Long-term follow-up for gene-edited immune cell therapy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study checks how people are doing years after receiving a specific company’s gene-edited immune cell treatment. It helps researchers learn about long-term safety and health outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your parent/guardian) previously received Pell’s lentiviral-based gene-edited immune cell in a clinical trial
- Your last infusion of that gene-edited cell was within the last 15 years
- You (or your parent/guardian) can sign informed consent and agree to follow the study rules
- The study is a long-term follow-up, not an additional treatment you may be receiving now
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for patients with large B-cell lymphoma who did not respond well to CAR-T cell therapy (a type of immunotherapy). The study uses tumor testing to guide which drugs to use, aiming to help patients whose cancer has stopped responding or is growing again.
This study is a long-term follow-up for people who have already received the GF-CART01 treatment in a previous study. It checks how safe the treatment stays over time and how long the effects last.
This study checks in with people who already received CAR-T therapy to learn how they’re doing over time. It may help doctors understand the long-term benefits and side effects of CAR-T for future patients.
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
This study is a long-term check-in for people who previously received gene-modified T-cell infusions in a related Celgene/Juno/BMS trial. It helps researchers track safety and long-term effects over time.
This study checks long-term health after receiving a gene-modified cell therapy through a St. Jude study. It helps doctors understand the treatment’s lasting effects and safety over time.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.